Charlotte’s Web Earnings Call: BAT Deal, Medicare Upside

Charlotte’s Web Holdings (OTC) ((TSE:CWEB)) has held its Q4 earnings call. Read on for the main highlights of the call.

Charlotte’s Web’s latest earnings call struck a cautiously optimistic tone, blending major strategic wins with lingering financial and regulatory risks. Management highlighted balance-sheet repair, new federal healthcare pathways, and tighter cost controls as catalysts for a path to profitability, while stressing that revenue benefits will materialize gradually and depend on key approvals.

BAT deal clears debt and injects new capital

British American Tobacco will convert a $55M debenture plus about $10M of interest into equity at CAD 0.94 and add a $10M private placement, taking its total commitment to roughly $75M. The move wipes out the company’s largest liability, removes about $3M in annual interest over the next 3.5 years, simplifies the capital structure, and leaves BAT owning around 40%.

Medicare pilot opens a new federal access channel

New CMS guidance created the Substance Access BEI, allowing hemp-derived full‑spectrum CBD products with up to 3 mg THC per serving in select CMMI pilots. Starting April 1, ACO REACH and the Enhanced Oncology Model can spend up to $500 per beneficiary annually for eligible products across an initial pool of about 2M Medicare patients, with Charlotte’s Web preparing portals and outreach to physicians.

DeFloria advances toward Phase II and pharma optionality

Affiliate DeFloria, of which Charlotte’s Web owns roughly one-third, secured FDA clearance to begin Phase II trials for a botanical drug targeting irritability in autism spectrum disorder. If the product is ultimately approved, Charlotte’s Web holds exclusive commercial manufacturing rights, opening a higher-value pharmaceutical revenue stream and helping validate the company’s genetics and science platform.

Revenue returns to growth after a multi-year decline

Fourth-quarter consolidated net revenue reached $13.3M, up 15.8% from Q3 and 4.7% from the prior-year quarter’s $12.7M. For the full year, revenue edged up 0.5% to $49.9M, marking the first annual increase since 2021 and signaling that the business may have found a base from which to grow.

Margins pressured by one-time charge but trending higher

Fourth-quarter gross profit was $5.0M with a reported gross margin of 37.5%, depressed by a $1.3M nonrecurring write-off of legacy gummy inventory. Management noted that this disposal shaved roughly 10 percentage points off margin while in-house manufacturing added about 400 basis points, and it expects gross margin to move back toward a roughly 50% historical level as temporary items roll off.

Deep cuts in SG&A support a smaller, leaner cost base

Full‑year SG&A dropped to $42.0M from $53.3M, a 21.2% year-over-year reduction that caps a roughly 44.5% cut over two years, saving an estimated $33.6M annually. Operating loss improved by more than 36% to $20.3M from $32.0M, demonstrating that restructuring and expense discipline are meaningfully narrowing the company’s operating deficit.

Cash burn improves and liquidity set to strengthen

Net cash used in operating activities in Q4 fell to $1.9M, better than both the prior quarter’s $5.5M outflow and similar to the year-ago period. Year-end cash was $8.0M with working capital of $21.7M, and management underscored that the additional $10M from BAT’s private placement should provide a significant liquidity buffer if shareholders approve the transaction.

Compliance credentials bolster healthcare ambitions

Charlotte’s Web completed its annual NSF dietary supplement GMP audit with zero findings, which management called the industry gold standard. This clean result supports the company’s push into healthcare settings, strengthening its case with federal programs and provider groups that increasingly demand rigorous quality and safety credentials.

Persistent net losses and a weaker Q4 bottom line

Despite operational progress, the company remains in the red, posting a Q4 net loss of $11.4M or $0.07 per share compared with a $3.4M loss or $0.02 per share a year earlier. For the full year, net loss held roughly flat at $29.7M or $0.19 per share, underscoring that further revenue growth and margin expansion are still needed to reach break-even.

One-time inventory cleanup weighs on quarterly results

Management highlighted that the $1.3M legacy gummy inventory disposal was a discrete event that significantly distorted Q4 metrics. The charge not only cut gross margin by about 10 percentage points but also affected the reported net loss, and the company emphasized that these items are not expected to recur going forward.

Regulatory crosscurrents create material strategic risk

The company flagged a proposed hemp rule effective November 2026 that could cap THC at 0.4 mg per container, a shift management warned could effectively demolish much of the current market. This prospective restriction clashes with CMS guidance allowing up to 3 mg THC per serving in pilots, leaving the company navigating conflicting federal signals that may slow adoption and investment.

New growth drivers expected to ramp slowly

While the CMMI pilots represent a potentially significant new channel, management cautioned that revenue will likely build gradually over 12 to 18 months. A larger Medicare Advantage opportunity remains dependent on future rulemaking, meaning that investors should temper near-term expectations for 2026 and view these programs as longer-term growth levers.

Liquidity hinges on closing the BAT transaction

With just $8.0M in cash at year-end and ongoing operating losses, Charlotte’s Web acknowledges a sensitive liquidity position. The balance sheet benefits and $10M cash infusion from BAT require independent shareholder approval of the conversion and private placement, creating timing and execution risk around a transaction central to the company’s financial plan.

Dilution and concentrated ownership concerns

BAT’s debenture conversion and new equity investment will leave it holding about 40% of the company on a non-diluted basis, with a contractual cap at 49%. While management pointed to governance protections, the sizable stake means existing shareholders face meaningful dilution and must consider the implications of a single strategic investor wielding significant influence.

Competition inside the Medicare pilot channel

The CMMI benefit is explicitly nonexclusive, allowing accountable care organizations to procure qualifying hemp-derived products from multiple suppliers. Charlotte’s Web’s success will therefore hinge on rapid provider education, evidence of clinical outcomes, and quality differentiation to win share against other brands rather than relying on structural exclusivity.

Nonrecurring SG&A items add near-term noise

Fourth-quarter SG&A included discrete items such as a roughly $600K state sales tax audit accrual and certain contract termination and timing adjustments. These factors added volatility to near-term operating expenses, and management indicated that they distort the underlying run-rate SG&A, which it pegs at about $10M to $11M per quarter before Medicare launch spending.

Guidance points to gradual, scalable profitability

Management guided toward a model where normalized gross margins return to around 50% and quarterly SG&A holds near $10M to $11M, excluding Medicare launch costs. With revenue growing, operating loss already down more than 36%, cash used in operations improving, and the BAT deal set to remove interest expense and add $10M in capital, the company argues it is positioned for a gradual but scalable path to profitability as Medicare pilots and DeFloria progress.

Charlotte’s Web’s earnings call painted a picture of a business at an inflection point, pairing substantial financial restructuring and federal-channel access with real but manageable risks. For investors, the near term remains volatile, yet the combination of a cleaner balance sheet, cost discipline, and emerging healthcare and pharma channels could materially reshape the company’s long-term value if execution and regulation break its way.